Roche Sees Pegasys Approval Delay Until 2002, But With Broader Indication

Roche's "current expectation" for the pegylated interferon product Pegasys is that it will be approved in the first half of 2002, with an indication covering both monotherapy and combination use.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet